Effectiveness of Cetuximab in Combination with Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A 1:2 Propensity Score-matched Analysis
Conclusions: This study reveals that patients with locoregionally advanced NPC could benefit from the addition of cetuximab to CCRT, and this therapeutic gain mainly originated from T4 and/or N3 subgroup although suffering more acute moderate to severe toxicities.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Li-Rong Wu, Huan-feng Zhu, Jianhua Xu, Xue-song Jiang, Li Yin, Ning Jiang, Dan Zong, Fei-jiang Wang, Sheng-fu Huang, Xiu-hua Bian, Jian-feng Wu, Dan Song, Wen-jie Guo, Ju-Ying Liu, Xia He Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Erbitux | Nasopharyngeal Cancer | Oral Cancer | Oropharyngeal Cancer | Study | Toxicology